Leucettinib-21

N/A

Report date: 2023/12/13 14:04:38
NME

Base Information

Drug NameLeucettinib-21
Drug Alias NameLCTB-21
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors
TargetsDual-specificity tyrosine-phosphorylation regulated kinase 1A
Therapy Area/IndicationsDown SyndromeAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPerha Pharmaceuticals SAS
China Registration ClassN/A

Develop Information

Active CompaniesPerha Pharmaceuticals SAS
Inactive CompaniesN/A
Active IndicationsDown SyndromeAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A